https://www.cochrane.org/evidence/CD011661_etrolizumab-treatment-active-ulcerative-colitis
Etrolizumab for the treatment of active ulcerative colitis | Cochrane
for theulcerative colitisetrolizumabtreatmentactive
https://www.roche.com/investors/updates/inv-update-2020-08-10
Roche provides update on phase III studies of etrolizumab in people with moderately to severely...
Etrolizumab met its primary endpoint of inducing remission versus placebo for people with ulcerative colitis in only two of three studies Etrolizumab failed to...
https://www.cochrane.org/fr/evidence/CD011661_etrolizumab-treatment-active-ulcerative-colitis
Etrolizumab for the treatment of active ulcerative colitis | Cochrane
for theulcerative colitisetrolizumabtreatmentactive